U.S. FDA Grants Expanded Approval for VONVENDI® [Recombinant Von Willebrand Factor] for Adults and Children with Von Willebrand Disease
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 06 2025
0mins
Source: Newsfilter
FDA Approval: The FDA has approved VONVENDI for routine prophylaxis to reduce bleeding episodes in adults with Type 1 and 2 Von Willebrand Disease (VWD), as well as for on-demand and perioperative management in pediatric patients.
Significance of VONVENDI: VONVENDI is the only recombinant von Willebrand factor replacement therapy approved for both adults and children with VWD, addressing a critical need for effective treatment in over 3 million affected individuals in the U.S.
Analyst Views on TAK
Wall Street analysts forecast TAK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TAK is 18.00 USD with a low forecast of 18.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 15.940
Low
18.00
Averages
18.00
High
18.00
Current: 15.940
Low
18.00
Averages
18.00
High
18.00
About TAK
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
